[HTML][HTML] A study protocol for validation and implementation of whole-genome and-transcriptome sequencing as a comprehensive precision diagnostic test in acute …

E Berglund, G Barbany, C Orsmark-Pietras… - Frontiers in …, 2022 - frontiersin.org
Background: Whole-genome sequencing (WGS) and whole-transcriptome sequencing
(WTS), with the ability to provide comprehensive genomic information, have become the …

Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression

S Stratmann, SA Yones, M Garbulowski, J Sun… - Blood …, 2022 - ashpublications.org
Numerous studies have been performed over the last decade to exploit the complexity of
genomic and transcriptomic lesions driving the initiation of acute myeloid leukemia (AML) …

Mapping AML heterogeneity-multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses

JF Severens, EO Karakaslar, BA van der Reijden… - Leukemia, 2024 - nature.com
Subtyping of acute myeloid leukaemia (AML) is predominantly based on recurrent genetic
abnormalities, but recent literature indicates that transcriptomic phenotyping holds immense …

Glassonet: Identifying discriminative gene sets among molecular subtypes of breast cancer

S Liu, Y Zhang, X Shang - IEEE/ACM Transactions on …, 2022 - ieeexplore.ieee.org
Breast cancer is a heterogeneous disease caused by various alterations in the genome or
transcriptome. Molecular subtypes of breast cancer have been reported, but useful …

A comprehensive landscape of imaging feature-associated RNA expression profiles in human breast tissue

T Mou, J Liang, TN Vu, M Tian, Y Gao - Sensors, 2023 - mdpi.com
The expression abundance of transcripts in nondiseased breast tissue varies among
individuals. The association study of genotypes and imaging phenotypes may help us to …

Prediction model for drug response of acute myeloid leukemia patients

QT Trac, Y Pawitan, T Mou, T Erkers, P Östling… - NPJ Precision …, 2023 - nature.com
Despite some encouraging successes, predicting the therapy response of acute myeloid
leukemia (AML) patients remains highly challenging due to tumor heterogeneity. Here we …

[HTML][HTML] 5-methylcytosine RNA modification regulators-based patterns and features of immune microenvironment in acute myeloid leukemia

Y Ding, AK Bajpai, F Wu, W Lu, L Xu, J Mao, Q Li… - Aging (Albany …, 2024 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is a highly heterogeneous malignant disease of the blood
cell. The current therapies for AML are unsatisfactory and the molecular mechanisms …

Role of Diacylglycerol Kinases in Acute Myeloid Leukemia

T Gravina, CMT Boggio, E Gorla, L Racca, S Polidoro… - Biomedicines, 2023 - mdpi.com
Diacylglycerol kinases (DGKs) play dual roles in cell transformation and
immunosurveillance. According to cancer expression databases, acute myeloid leukemia …

Integrated transcriptional analysis reveals gene expression-based AML subtypes with distinct outcomes and drug responses

JF Severens, EO Karakaslar, BA van der Reijden… - medRxiv, 2023 - medrxiv.org
Subtyping of acute myeloid leukaemia (AML) has made significant progress, exemplified by
the recent classification updates by the World Health Organization and International …

Characterization of the molecular heterogeneity in acute myeloid leukemia for effective targeting of disease-driving leukemic stem cells

AM Leppä - 2024 - archiv.ub.uni-heidelberg.de
The human body is made of trillions of cells that are the building blocks of all living things.
Hematopoietic cells are a set of such building blocks. They are made in the bone marrow …